- Home
- HSPO vs CMRX Comparison
HSPO vs CMRX Comparison
Compare HSPO & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSPO
- CMRX
- Stock Information
- Founded
- HSPO 2014
- CMRX 2000
- Country
- HSPO United States
- CMRX United States
- Employees
- HSPO N/A
- CMRX N/A
- Industry
- HSPO Blank Checks
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- HSPO Finance
- CMRX Health Care
- Exchange
- HSPO Nasdaq
- CMRX Nasdaq
- Market Cap
- HSPO 87.7M
- CMRX 77.0M
- IPO Year
- HSPO 2022
- CMRX 2013
- Fundamental
- Price
- HSPO $11.25
- CMRX $0.93
- Analyst Decision
- HSPO
- CMRX Strong Buy
- Analyst Count
- HSPO 0
- CMRX 1
- Target Price
- HSPO N/A
- CMRX $11.00
- AVG Volume (30 Days)
- HSPO 27.4K
- CMRX 119.4K
- Earning Date
- HSPO 01-01-0001
- CMRX 11-08-2024
- Dividend Yield
- HSPO N/A
- CMRX N/A
- EPS Growth
- HSPO N/A
- CMRX N/A
- EPS
- HSPO 0.33
- CMRX N/A
- Revenue
- HSPO N/A
- CMRX $144,000.00
- Revenue This Year
- HSPO N/A
- CMRX $3,040.12
- Revenue Next Year
- HSPO N/A
- CMRX N/A
- P/E Ratio
- HSPO $34.26
- CMRX N/A
- Revenue Growth
- HSPO N/A
- CMRX N/A
- 52 Week Low
- HSPO $10.60
- CMRX $0.75
- 52 Week High
- HSPO $11.25
- CMRX $1.30
- Technical
- Relative Strength Index (RSI)
- HSPO 69.42
- CMRX 60.78
- Support Level
- HSPO $11.17
- CMRX $0.80
- Resistance Level
- HSPO $11.25
- CMRX $0.98
- Average True Range (ATR)
- HSPO 0.00
- CMRX 0.05
- MACD
- HSPO 0.00
- CMRX 0.01
- Stochastic Oscillator
- HSPO 100.00
- CMRX 83.33
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.